Cocrystal Pharma, Inc. (COCP) AI Stock Analysis

Cocrystal Pharma, Inc. is a biotechnology company focused on the discovery and advancement of antiviral therapeutics for serious and chronic viral diseases using structure-based technologies. Its pipeline targets hepatitis C virus (HCV), influenza virus, coronaviruses, and norovirus. Its lead compound, CC-31244, is a non-nucleoside polymerase inhibitor for HCV that has completed Phase IIa clinical trials. The company is also developing CC-42344, a preclinical PB2 inhibitor targeting influenza infections, as well as non-nucleoside polymerase inhibitors for norovirus. Cocrystal Pharma collaborates with partners including Merck Sharp & Dohme Corp. for influenza A/B antiviral agents, as well as Kansas State University Research Foundation, HitGen, and InterX Inc.

Cocrystal Pharma has experienced highly volatile annual revenue driven by collaboration activities. Annual revenue rose from $78,000 in FY2015 to $6.6M in FY2019, before declining 69.3% to $2.0M in FY2020. In FY2021, revenue rebounded 169.5% to $5.4M, while net losses stood at -$14.2M and free cash flow was -$12.8M. For the trailing twelve months, revenue was $330,000 with a net margin profile reflecting substantial operating losses, including an operating margin of -3032.4%. For the latest quarter ended June 30, 2026, quarterly revenue grew 26.9% year-over-year.

As of June 30, 2026, Cocrystal Pharma held $2.2M in cash and short-term investments alongside total debt of $1.3M, yielding net cash of $828,000. Total assets were $4.6M against shareholders' equity of $1.0M. The company reported a current ratio of 1.24 and a debt-to-equity ratio of 1.28. In FY2025, capital expenditures were $12,000, while the company's share count increased 90.0% over the past 5 years.

Cocrystal Pharma trades at a market capitalization of $19.6M and an enterprise value of $21.9M. The stock trades at a price-to-sales multiple of 59.5x and an enterprise value to revenue multiple of 66.4x, both significantly higher than the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. Its EV to EBITDA ratio is 0.7x, compared to 12.0x for the peer median. Over the past year, COCP shares returned -4.7%, underperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year span, the stock returned -91.0% compared to an 83.0% gain for the benchmark.

Wall Street coverage includes 2 Strong Buy ratings, with zero Buy, Hold, or Sell recommendations. The mean price target is $8.00, representing a 684.3% premium over the last close of $1.02. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.72 and revenue of $110.0M. For the next fiscal year, 2 analysts project an EPS of -$0.47 and revenue of $0. Cocrystal Pharma has beaten EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of Cocrystal Pharma, Inc. (COCP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: COCP income statement, COCP balance sheet, COCP key metrics, COCP analyst forecast, COCP chart. See the COCP stock overview for the latest quote and news.